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BACKGROUND
Cirrhosis is one of the most frequent and
severe chronic diseases worldwide. In the
initial stages it has few or no symptoms,
but advanced stages of cirrhosis are char-
acterised by reduced liver function,
complications due to portal hypertension
and neuroendocrine abnormalities with
increased activity of the sympathetic
nervous system (SNS) and renin-aldoste-
rone axis. The prognosis is severe, with an
increasing frequency of complications
including variceal bleeding, ascites and
spontaneous infections with subsequent
development of hepatic encephalopathy
and hepatorenal syndrome. More than
one-third of patients diagnosed with
cirrhosis develop oesophageal varices
within 3 years after the diagnosis is made.
Varices develop and later bleed when the
portal pressure is increased and the hepatic
vein pressure gradient (HVPG) is more
than 10e12 mm Hg. Life-threatening
spontaneous bacterial infections are
another common complication of
advanced cirrhosis. The infections are
mainly triggered by gut bacterial trans-
location, which is the migration of
microorganisms from the intestinal lumen
to the mesenteric lymph nodes or other
extraintestinal sites.1 Small intestinal
bacterial overgrowth of Gram-negative
rods, structural and functional alterations
of the intestinal mucosa and deﬁciencies
in defence mechanisms contribute to
bacterial translocation.2 Increased serum
levels of lipopolysaccharide binding
protein and circulating bacterial DNA are
markers of bacterial translocation and
both predict a poor outcome in cirrhosis
and ascites.3 4 Selective gut decontamina-
tion prevents spontaneous bacterial infec-
tions and improves survival in advanced
cirrhosis.5
Non-selective b-blockers (BB) are the
only drugs shown to improve survival in
patients with cirrhosis and medium to
large oesophageal varices.6 BB inhibit the
binding of catecholamines (norepinephrine
and epinephrine) to the b1 and
b2 adrenoreceptors. b1 blockade reduces
the cardiac output and b2 blockade
leads to splanchnic vasoconstriction. The
combined inhibition of b1 and b2 adre-
noreceptors is necessary to achieve a sufﬁ-
cient reduction in portal pressure. The
beneﬁt of BB has been attributed to portal
pressure reduction which decreases the
risk of variceal bleeding as well as other
complications of portal hypertension.7e10
There is increasing evidence to suggest
that BB also have non-haemodynamic
effects and that they may be ineffective in
early cirrhosis and may be detrimental
in certain patients with end-stage
cirrhosis.11e13 In the present paper
we propose that the beneﬁt of BB is
related both to haemodynamic and non-
haemodynamic effects during a window in
the cirrhotic disease. Outside the thera-
peutic window, BB may be ineffective or
even have detrimental effects.11e13
NON-HAEMODYNAMIC EFFECTS OF BB
Clinical evidence
To assess a possible beneﬁcial effect of BB
in cirrhosis beyond the reduced risk of
variceal bleeding, we performed a meta-
analysis of eight randomised trials with
970 patients comparing BB and isosorbide
mononitrate (IsMn) with banding ligation
for patients with oesophageal varices and
previous variceal bleeding.14 The mean
dose of BB was 48e120 mg/day and the
mean dose of IsMn was 30e60 mg/day. In
total, 98 of 480 patients randomised to BB
and IsMn and 121 of 490 patients rando-
mised to banding ligation died. Thus, BB
and IsMn reduced mortality compared
with banding ligation (RR 0.78, 95% CI
0.64 to 0.96). There were no apparent
differences between treatment groups in
the risk of upper gastrointestinal bleeding
(RR 1.15, 95% CI 0.81 to 1.63), variceal
rebleeding (RR 1.23, 95% CI 0.74 to 2.06)
or bleeding-related mortality (RR 0.75,
95% CI 0.37 to 1.50). These ﬁndings
suggest that the reduced mortality did not
reﬂect reduced bleeding rates. Additional
effects that are not related to the risk
of variceal bleeding may exist. The data
in the meta-analysis did not allow for
an assessment of the reasons for the
survival beneﬁt. However, a meta-analysis
of randomised trials and observational
studies found that BB may reduce the risk
of spontaneous bacterial peritonitis,8 an
effect that was independent of the portal
pressure response to BB.
Experimental evidence
In the early stages of cirrhosis the activity
of the SNS is close to normal levels. SNS
activity increases with the severity of
cirrhosis. In end-stage cirrhosis the SNS is
highly active. Fibres from the SNS termi-
nate in blood vessels, gut-associated
lymphatic tissue and the intestinal
mucosa. The level of norepinephrine
increases with the activity of the SNS. In
the intestinal lumen, norepinephrine is
absorbed by gut bacteria resulting in an
increased growth of Escherichia coli and
other Gram-negative bacteria.15 16 The
absorption also increases the bacterial
virulence and ability to adhere to the gut
mucosa.15 16 The increased norepinephrine
levels are also known to decrease the
intestinal transit time, impair the mucosal
barrier function and inhibit chemotaxis
and phagocytosis.17 In experimental
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cirrhosis, splanchnic sympathectomy
and BB reduce the rate of spontaneous
bacterial translocation and migration of
E coli to the peritoneal cavity and the
bloodstream.18 19
THE THERAPEUTIC WINDOW OF BB
We hypothesise that BB improve survival
in cirrhosis during a certain window in the
disease (ﬁgure 1).
When does the window open?
BB have no clear effects in early cirrhosis
without varices or ascites.13 At this stage
of cirrhosis the portal pressure is increased
but has not reached the threshold value of
10 mm Hg. The SNS is not substantially
activated and the splanchnic blood ﬂow is
normal. Clinical trials have not found
beneﬁcial effects of BB on clinical end-
points (ie, complications of portal hyper-
tension or death) in this patient group.13
Indeed, BB fail to reduce portal pressure in
patients with an HVPG <10 mm Hg.20
As the portal pressure increases the SNS
becomes increasingly activated and gut
bacterial translocation and splanchnic
hyperaemia occur.21 Medium to large
oesophageal varices and ascites develop.
The current treatment recommendations
specify that BB should not be used before
medium to large oesophageal varices are
developed. The experimental evidence
suggests that the non-haemodynamic
effects begin when gut bacterial trans-
location is seen at the stage of decom-
pensated cirrhosis with ascites.
Pathological gut bacterial translocation
does not occur in experimental cirrhosis
until ascites appears.19 22 In observational
studies, bacterial translocation is seen
in patients with advanced (Child C)
cirrhosis but not in those with earlier
stages of the disease (Child AeB).23
The exact time when the therapeutic
window opens may be debated. The
question may be answered in an ongoing
multicentre randomised controlled trial
(NCT01059396) which is being conducted
to assess whether BB decrease the risk
of decompensation in patients with
compensated cirrhosis and portal hyper-
tension with an HVPG >10 mm Hg.
When does the window close?
End-stage cirrhosis is associated with
pronounced circulatory changes and high
SNS activity. Both aspects may inﬂuence
the upper limit of the therapeutic window.
< In end-stage cirrhosis the circulatory
changes are related to the cardiac
output, which is increased to preserve
blood pressure and organ perfusion due
to the peripheral vasodilation. The
result is a gradual decrease in the
cardiac compensatory reserve. Mainte-
nance of an increased cardiac output
improves survival.24 25 Conversely,
a fall in the cardiac output is associated
with the development of hepatorenal
syndrome and has a negative impact on
survival.24 26 BB are cardio-inhibitory
and reduce the cardiac output and the
cardiac compensatory reserve.
< Patients with refractory ascites have
increased levels of proinﬂammatory
cytokines in the splanchnic compart-
ment. Chronic inﬂammation may
induce a b to a adrenergic shift with
a reduced expression of b-adrenergic
receptors and loss of sympathetic nerve
ﬁbres.27 The effects of BB are thereby
diminished.
The combined evidence suggests that
the beneﬁcial effects of BB are lost in end-
stage cirrhosis (ﬁgure 1). In theory, BB
may have detrimental effects in end-stage
cirrhosis due to their negative effect on
the cardiac compensatory reserve. An
observational study found that BB may
decrease survival in advanced cirrhosis
with refractory ascites.11 The patients in
the study were not randomised to receive
BB. Confounding by indication may
inﬂuence the overall results. Since the
choice to treat the included patients with
BB may reﬂect underlying prognostic
factors (known and unknown), the
evidence does not allow for clear treat-
ment recommendations. However, we
believe that high doses of BB need to be
used with great care or perhaps avoided in
patients with refractory ascites.
SUGGESTIONS FOR FUTURE RESEARCH
Additional evidence is needed to deter-
mine the non-haemodynamic effects of BB
and the therapeutic window for them.
However, performing trials or studies to
test these questions is very difﬁcult. At
present we have no reliable methods to
test the effects of BB on the SNS activity
in the splanchnic compartment. The
plasma concentrations of norepinephrine
are unreliable because they depend on
the release rate and clearance from the
plasma pool and because post-synaptic
concentrations may be up to 1000 times
higher than plasma levels. In theory,
the non-haemodynamic effects of BB may
be identiﬁed in large multicentre multi-
national randomised controlled trials
comparing BB with placebo. One potential
outcome measure could be spontaneous
bacterial peritonitis, which is a clinical
marker of gut bacterial translocation.
The trial would have to include patients
with ascites but exclude those with
medium to large varices for ethical
reasons. Considering that several patients
have contraindications to BB or decline
participation, the number of patients to be
screened would be considerable. Alterna-
tively, it would be possible to use surro-
gate markers of bacterial translocation
such as increased serum lipopolysaccha-
ride binding protein or circulating frag-
ments of bacterial DNA as outcome
measures.3 4Figure 1 Hypothesis of the therapeutic window for non-selective b-blockers (BB) in cirrhosis.
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Conventional echocardiography is not
useful for assessing the cardiac compensa-
tory reserve. First, it is dependent on age
and the preload and afterload condition.
Second, systolic dysfunction or impaired
reserve is subclinical at rest and will only be
clinically signiﬁcant with increasing circu-
latory demands as seen during acute
complications. This takes a cardiac stress
test to unmask. This has not been studied
prospectively in advanced cirrhosis and cut-
off values cannot be recommended. Cardiac
output in advanced cirrhosis may be
inﬂuenced intrinsically due to reduced
contractility or impaired chronotropic
responses, but it is also highly dependent
on the preload and afterload condition.
Potential options include a dobutamine test
or an afterload test with a loading inde-
pendent echocardiography measure or MRI
to assess the rise or fall in left ventricular
ejection fraction, respectively.28e31 Tread-
mill testing is difﬁcult in patients with
advanced cirrhosis as they are often in poor
shape, have muscle wasting and may also
have pulmonary dysfunction.
Current evidence supports the notion
that BB act in cirrhosis through haemo-
dynamic and non-haemodynamic mecha-
nisms in a window period of cirrhosis. The
non-haemodynamic effects of BB may
improve survival in a proportion of
patients with cirrhosis and ascites with
repeated gut bacterial translocation and
no (or small) oesophageal varices. These
patients are not offered BB today. Addi-
tional clinical and experimental research is
needed to analyse the effects of BB in
different stages of the disease and
to identify valid surrogate markers for
clinical outcome measures.
Funding AA is supported by grant nos PS09/00485 and
PI051871 (CIBERehd) from the Spanish Ministry of
Science. CIBERhed is funded by the Instituto de Salud
Carlos III.
Competing interests None.
Contributors All authors contributed to concept and the
writing and review of the paper and all have approved
the final version.
Provenance and peer review Commissioned;
externally peer reviewed.
Revised 29 November 2011
Accepted 15 December 2011
Published Online First 10 January 2012
Gut 2012;61:967e969. doi:10.1136/gutjnl-2011-301348
REFERENCES
1. Berg RD, Garlington AW. Translocation of certain
indigenous bacteria from the gastrointestinal tract to
the mesenteric lymph nodes and other organs in
a gnotobiotic mouse model. Infect Immun
1979;23:403e11.
2. Wiest R, Garcia-Tsao G. Bacterial translocation (BT)
in cirrhosis. Hepatology 2005;41:422e33.
3. Albillos A, de-la-Hera A, varez-Mon M. Serum
lipopolysaccharide-binding protein prediction of
severe bacterial infection in cirrhotic patients with
ascites. Lancet 2004;363:1608e10.
4. Zapater P, Frances R, Gonzalez-Navajas JM, et al.
Serum and ascitic fluid bacterial DNA: a new
independent prognostic factor in noninfected patients
with cirrhosis. Hepatology 2008;48:1924e31.
5. Terg R, Fassio E, Guevara M, et al. Ciprofloxacin in
primary prophylaxis of spontaneous bacterial
peritonitis: a randomized, placebo-controlled study. J
Hepatol 2008;48:774e9.
6. de Franchis R. Revising consensus in portal
hypertension: report of the Baveno V consensus
workshop on methodology of diagnosis and therapy in
portal hypertension. J Hepatol 2010;53:762e8.
7. Albillos A, Banares R, Gonzalez M, et al. Value of the
hepatic venous pressure gradient to monitor drug
therapy for portal hypertension: a meta-analysis. Am
J Gastroenterol 2007;102:1116e26.
8. Senzolo M, Cholongitas E, Burra P, et al. Beta-
blockers protect against spontaneous bacterial
peritonitis in cirrhotic patients: a meta-analysis. Liver
Int 2009;29:1189e93.
9. D’Amico G, Garcia-Pagan JC, Luca A, et al. Hepatic
vein pressure gradient reduction and prevention of
variceal bleeding in cirrhosis: a systematic review.
Gastroenterology 2006;131:1611e24.
10. Abraldes JG, Tarantino I, Turnes J, et al.
Hemodynamic response to pharmacological
treatment of portal hypertension and long-term
prognosis of cirrhosis. Hepatology 2003;37:902e8.
11. Serste T, Melot C, Francoz C, et al. Deleterious
effects of beta-blockers on survival in patients with
cirrhosis and refractory ascites. Hepatology
2010;52:1017e22.
12. Serste T, Francoz C, Durand F, et al. Beta-blockers
cause paracentesis-induced circulatory dysfunction in
patients with cirrhosis and refractory ascites: a cross-
over study. J Hepatol 2011;55:794e9.
13. Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-
blockers to prevent gastroesophageal varices in patients
with cirrhosis. N Engl J Med 2005;353:2254e61.
14. Krag A, Wiest R, Gluud LL. Reduced mortality with
non-selective beta-blockers compared to banding is
not related to prevention of bleeding or bleeding
related mortality: systematic review of randomized
trials. J Hepatol 2011;54:S72.
15. Freestone PP, Williams PH, Haigh RD, et al. Growth
stimulation of intestinal commensal Escherichia coli
by catecholamines: a possible contributory factor in
trauma-induced sepsis. Shock 2002;18:465e70.
16. Green BT, Lyte M, Chen C, et al. Adrenergic
modulation of Escherichia coli O157:H7 adherence to
the colonic mucosa. Am J Physiol Gastrointest Liver
Physiol 2004;287:G1238e46.
17. Sanders VM, Straub RH. Norepinephrine, the beta-
adrenergic receptor, and immunity. Brain Behav
Immun 2002;16:290e332.
18. Worlicek M, Knebel K, Linde HJ, et al. Splanchnic
sympathectomy prevents translocation and spreading
of E coli but not S aureus in liver cirrhosis. Gut
2010;59:1127e34.
19. Perez-Paramo M, Munoz J, Albillos A, et al. Effect
of propranolol on the factors promoting bacterial
translocation in cirrhotic rats with ascites. Hepatology
2000;31:43e8.
20. Qamar AA, Groszmann RJ, Grace ND, et al. Lack of
effect of non-selective beta-blockers on the hepatic
venous pressure gradient (HVPG) in patients with mild
portal hypertension: a tale of two studies. Hepatology
2010;52:1020A.
21. Wiest R, Groszmann RJ. The paradox of nitric oxide
in cirrhosis and portal hypertension: too much, not
enough. Hepatology 2002;35:478e91.
22. Garcia-Tsao G, Lee FY, Barden GE, et al. Bacterial
translocation to mesenteric lymph nodes is increased
in cirrhotic rats with ascites. Gastroenterology
1995;108:1835e41.
23. Cirera I, Bauer TM, Navasa M, et al. Bacterial
translocation of enteric organisms in patients with
cirrhosis. J Hepatol 2001;34:32e7.
24. Ruiz-del-Arbol L, Monescillo A, Arocena C, et al.
Circulatory function and hepatorenal syndrome in
cirrhosis. Hepatology 2005;42:439e47.
25. Ruiz-del-Arbol L, Urman J, Fernandez J, et al.
Systemic, renal, and hepatic hemodynamic
derangement in cirrhotic patients with spontaneous
bacterial peritonitis. Hepatology 2003;38:1210e18.
26. Krag A, Bendtsen F, Henriksen JH, et al. Low cardiac
output predicts development of hepatorenal
syndrome and survival in patients with cirrhosis and
ascites. Gut 2010;59:105e10.
27. Straub RH, Wiest R, Strauch UG, et al. The role of
the sympathetic nervous system in intestinal
inflammation. Gut 2006;55:1640e9.
28. Yotti R, Bermejo J, Desco MM, et al. Doppler-derived
ejection intraventricular pressure gradients provide
a reliable assessment of left ventricular systolic
chamber function. Circulation 2005;112:1771e9.
29. Ripoll C, Yotti R, Rincon D, et al. Increased baseline
systolic function in patients with cirrhosis is
associated with greater decrease in stress situations.
Hepatology 2011;54:1246A.
30. Krag A, Bendtsen F, Mortensen C, et al. Effects of
a single terlipressin administration on cardiac function
and perfusion in cirrhosis. Eur J Gastroenterol Hepatol
2010;22:1085e92.
31. Krag A, Bendtsen F, Kjaer A, et al. Cardiac function
studied by dobutamin stress MRI in patients with mild
cirrhosis. J Hepatol 2009;50:S277.
PAGE fraction trail=3
Gut July 2012 Vol 61 No 7 969
Leading article
group.bmj.com on September 5, 2017 - Published by http://gut.bmj.com/Downloaded from 
during a window in the disease
improve survival of patients with cirrhosis 
-blockersβnon-haemodynamic effects of 
The window hypothesis: haemodynamic and
Aleksander Krag, Reiner Wiest, Agustín Albillos and Lise Lotte Gluud
doi: 10.1136/gutjnl-2011-301348
2012 61: 967-969 originally published online January 10, 2012Gut 
 http://gut.bmj.com/content/61/7/967
Updated information and services can be found at: 
These include:
References
 #BIBLhttp://gut.bmj.com/content/61/7/967
This article cites 31 articles, 6 of which you can access for free at: 
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (331)Cirrhosis
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on September 5, 2017 - Published by http://gut.bmj.com/Downloaded from 
